Cargando…
Loading, please waitCargando…
Loading, please waitCondition Guide
A clinical, no-overpromises look at how mesenchymal stem cell (MSC) therapy is being studied as an adjunct for long COVID (post-COVID-19 condition, PASC): what the published trials actually show, the chronic-inflammation rationale, who is and isn't a candidate, and how Regeneris designs a personalized, COFEPRIS-regulated protocol at our clinic in Cancún, México.
Long COVID is a real, multisystem post-viral state driven in large part by persistent inflammation, immune dysfunction, and microvascular injury. Mesenchymal stem cell (MSC) therapy is INVESTIGATIONAL for this condition — early randomized and follow-up data suggest it is safe and may help quality of life, sleep, mood, and lung recovery, but it is not a cure. At Regeneris in Cancún, México, every patient receives a free medical evaluation first, and any plan is delivered as a personalized written quote — never an off-the-shelf package, never a published price.
What it actually is
Long COVID — formally called post-COVID-19 condition by the World Health Organization and post-acute sequelae of SARS-CoV-2 (PASC) by the U.S. National Institutes of Health — is a heterogeneous, multisystem state in which symptoms persist, relapse, or appear new beyond the acute infection. Most consensus definitions require symptoms lasting at least 12 weeks (three months) from the onset of SARS-CoV-2 infection and not explained by an alternative diagnosis. It can follow mild, moderate, or severe acute COVID-19, and it does not respect age or prior fitness.
What the published research shows
Mesenchymal stem cell therapy for long COVID is INVESTIGATIONAL. There is real preclinical and early clinical signal — but no MSC product is approved as a cure for post-COVID-19 condition by COFEPRIS, the U.S. FDA, or any equivalent regulator. The conservative way to read the evidence is: encouraging, mechanistically plausible, and worth offering as a carefully designed adjunct under physician supervision in Cancún, México — never as a guaranteed solution.
The first study to specifically enroll long COVID patients used three intravenous infusions of human umbilical-cord MSCs (UC-MSCs) and reported that the therapy was safe and well-tolerated, with potential improvement in sleep difficulty, depression, cognitive symptoms, and lung lesions on imaging. It is an early-stage signal, not a confirmatory trial.
A 36-month follow-up of a randomized, double-blind, placebo-controlled trial of MSC therapy in severe COVID-19 survivors showed that MSCs remained well-tolerated long-term and were associated with a higher general health score versus placebo, suggesting potential benefits for quality of life and lung recovery in patients with long COVID symptoms — although imaging normalization and pulmonary function differences were not statistically significant.
Who is — and isn't — a candidate
Not everyone with persistent post-COVID symptoms is a candidate, and being a candidate doesn't guarantee a result. The criteria below are general orientation; the final answer is always individualized in a medical evaluation at our Cancún, México clinic.
Regulation & location
Regeneris Therapy operates in Cancún, Quintana Roo, México — under federal oversight by COFEPRIS, México's national health regulator (the analog of the U.S. FDA). Long COVID protocols are designed within that regulatory framework, with cells sourced from COFEPRIS-certified laboratories, traceability documentation per dose, and physician supervision from medical evaluation through follow-up at our Cancún location.
Regeneris operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, México — the same federal authority that regulates pharmacies and hospitals across the country.
How we work
There is no off-the-shelf 'long COVID package' at Regeneris. Each plan is built case-by-case, after a free medical evaluation, and delivered as a personalized written quote — there are no prices published on this page or anywhere else on this site, because the model is medical evaluation first.
You send your history, symptom timeline, labs, and any imaging. A licensed physician on our Cancún, México team reviews the case, confirms a long COVID phenotype, and screens for any contraindication or alternative diagnosis that should be addressed first.
If MSC therapy is an appropriate option for you, we send a written plan: the proposed protocol (cell source, dose, route, sessions), the rationale, what to bring, and a transparent, personalized quote. No verbal pricing, no surprises.
You travel to Cancún for the in-clinic phase: physical exam, vitals, intravenous (and where indicated, local) MSC administration under physician supervision, observation, and a written summary.
Honest expectations
We do not promise cures. The published evidence on MSC therapy for long COVID is early-stage and outcomes vary; some patients report meaningful improvement in fatigue, sleep, mood, and exercise tolerance, others a partial response, others no change.
FAQ
The questions patients ask us most when considering stem cell therapy for long COVID and post-COVID syndrome in Cancún, México.
No — and any clinic that says so is misleading you. Mesenchymal stem cell (MSC) therapy for long COVID is INVESTIGATIONAL. The published trials (Tang 2024, Yuan 2025) report safety and signals of benefit for quality of life, sleep, mood, and lung recovery, but no MSC product is approved as a cure for post-COVID-19 condition by COFEPRIS, the FDA, or any equivalent regulator. At Regeneris in Cancún, México, we frame the therapy as an adjunct designed in a physician-led plan after a free medical evaluation — never as a guarantee.
This page is informational and does not constitute medical advice. Mesenchymal stem cell therapy is INVESTIGATIONAL for long COVID / post-COVID-19 condition; outcomes vary and no MSC product is approved as a cure for this condition by COFEPRIS, the U.S. FDA, or any equivalent regulator. Treatment decisions require an individualized evaluation with a licensed physician at our Cancún, México clinic; disclose all current medications, supplements, and conditions. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, Quintana Roo, México.
Book a free 15-min call with our team.
Send your history, symptom timeline, recent labs, and any imaging. A licensed physician at our Cancún, México clinic will review your case and tell you honestly whether MSC therapy is an option — with a personalized written quote after your free medical evaluation. No published prices, no off-the-shelf packages.
The current scientific consensus — summarized in major mechanistic reviews — is that long COVID is not a single disease but a family of interconnected biological drivers and downstream physiological consequences. That is why a single-target intervention rarely fixes it, and why a regenerative, anti-inflammatory approach is being studied as an adjunct in our clinic in Cancún, México.
A randomized clinical trial of three doses of UC-MSCs as adjunctive therapy in critically ill COVID-19 patients found the infusion safe and associated with reductions in ferritin, IL-6, and MCP-1/CCL2 by day 14, with improvements in immune markers sustained at four-month follow-up — supporting the anti-inflammatory mechanism that motivates MSC use in post-viral states.
A 2023 mechanistic review argues that MSCs and their secreted factors are a promising candidate for the post-acute neurological COVID syndrome because of their homing capacity, immunomodulatory effects, and paracrine signaling against neuroinflammation, neuronal injury, and oxidative stress — the same pathways implicated in 'brain fog' and persistent fatigue.
A 2024 Cell review of long COVID mechanisms describes 'upstream' drivers (viral persistence, inflammation, microclots, immune dysfunction) and 'downstream' consequences (endothelial dysfunction, small-fiber neuropathy, neurocognitive impairment). The authors emphasize that these mechanisms are interlocked, supporting integrated approaches over single-target drugs — the rationale for studying broad-acting regenerative tools.
Bottom line: MSC therapy for long COVID has a real early signal of safety and possible benefit, and a clear mechanistic rationale. It is still INVESTIGATIONAL, not curative, and outcomes vary. That is why every protocol at our Cancún, México clinic is preceded by a free medical evaluation, never sold as a guarantee.
Whether you are a candidate, and what an honest plan would look like for you, is a medical conversation — not a webpage decision. Disclose every medication, supplement, and diagnosis when you reach out.
Cells used in our long COVID protocols come from a COFEPRIS-certified laboratory with documented donor screening, viability, and characterization — never an unverified outside vial.
Every plan is evaluated, designed, and supervised by a licensed physician on-site at our Cancún, México clinic. Medical reviewer: Dra. Claudia Labastida (cédula profesional 12128801).
We follow up at defined intervals to track sleep, energy, cognition, exercise tolerance, and any objective markers your physician chose to monitor — and to decide honestly whether to repeat, adjust, or stop.
This is investigational, supervised regenerative care — not a sale. The right answer for your case may be MSC therapy, a layered protocol, or none of the above. The evaluation tells us.
If a clinic promises you a 'cure' for long COVID, walk away. Our promise is the opposite: a careful evaluation, an honest plan, supervised care in Cancún, México, and a transparent follow-up conversation about whether it worked.
The leading mechanistic models — summarized in a 2024 Cell review by Peluso and Deeks — describe long COVID as driven by persistent inflammation, immune dysfunction, microvascular injury, and possible viral persistence. Mesenchymal stem cells work mainly by paracrine signaling: they release exosomes, growth factors, and cytokines that modulate inflammation and recruit local repair cells across an entire system. That broad anti-inflammatory action is the biological rationale for studying them in a multisystem post-viral state, while acknowledging it does not address every driver and is not curative.
Several dedicated studies exist. Tang et al. (2024) gave three IV infusions of umbilical-cord MSCs to long COVID patients and reported the therapy was safe with potential improvement in sleep, depression, cognition, and lung lesions. Yuan et al. (2025) reported the 3-year follow-up of a randomized placebo-controlled MSC trial in severe COVID-19 survivors: long-term safety was supported and the MSC group had a higher general health score, although imaging and pulmonary function differences were not statistically significant. Rebelatto et al. (2022) randomized critically ill COVID-19 patients to UC-MSC infusions and reported reductions in ferritin, IL-6, and MCP-1/CCL2 by day 14, with benefits sustained at four months. Together, the evidence is encouraging and early-stage — not confirmatory.
Generally appropriate for evaluation: adults with documented prior SARS-CoV-2 infection, persistent symptoms beyond 12 weeks not explained by an alternative diagnosis, an inflammatory or fatigue-dominant phenotype, and the ability to travel safely to Cancún, México. Generally not appropriate without specialist oversight: active or recently treated cancer, active uncontrolled infection, uncontrolled immunosuppression, unstable cardiopulmonary disease, or pregnancy and lactation. The final answer is individualized in a free medical evaluation — please disclose every medication, supplement, and diagnosis.
There is no published price on this page or anywhere else on this site, and there is no off-the-shelf 'long COVID package.' The model is: free medical evaluation first, then a personalized written quote that reflects your case — cell source, dose, route, number of sessions, and what to bring. The in-clinic phase is performed in Cancún, México under physician supervision, followed by structured follow-up. If you ask for verbal pricing before evaluation, we will respectfully redirect you to the evaluation step.
Effects build gradually. The anti-inflammatory action of MSC therapy typically shows over weeks, with quality-of-life improvements — sleep, mood, energy, exercise tolerance — emerging over the following one to three months in patients who respond. Some patients report little or no change, and we will tell you that honestly at follow-up. Long COVID is multisystem; meaningful improvement, when it occurs, is most often partial rather than a full return to pre-COVID baseline, and is best assessed alongside rehabilitation, pacing, and treatment of any identified comorbidities.
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.
How COFEPRIS oversight, certified lab sourcing, and physician supervision shape the safety profile of regenerative care in Cancún.